Phase II study of high-dose @entity2664 in the treatment of recurrent XXXX of the @entity135 .

@entity1 @entity135 @entity137 @entity5 @entity957 @entity2664 @entity281 @entity3028
Sixteen consenting @entity1 with @entity957 of the @entity135 recurrent after surgery and irradiation were treated with i.v. @entity2664 . The @entity2664 dose given to most @entity1 was 16 mg/m2. Two @entity1 older than 70 years old and one performance status 3 @entity1 received a slightly lower dose (14 mg/m2). Two @entity1 who died less than 3 weeks after treatment were considered unevaluable for response. Of the 14 evaluable @entity1 , eight (57%) were stable (including three with @entity5 shrinkage less than 50%) and six (43%) failed. There were no major responses. Most treatment courses resulted in @entity3028 , but this was rapidly reversible and not associated with major @entity281 . Other @entity137 was generally mild to moderate. Based on this study, we conclude that @entity2664 has minimal activity against @entity957 of the @entity135 . Studies of the drug in other @entity5 types at doses of 16 mg/m2 or higher may be warranted.
